Review of clinical research on antiplatelet therapy in percutaneous coronary intervention in 2023
10.3969/j.issn.1004-8812.2024.01.002
- VernacularTitle:经皮冠状动脉介入治疗术后抗血小板治疗2023年度进展
- Author:
Hong-Bing YAN
1
;
Yong HUO
Author Information
1. 中国医学科学院阜外医院深圳医院, 广东深圳 518057
- Publication Type:Journal Article
- Keywords:
Percutaneous coronary intervention;
Antiplatelet therapy
- From:
Chinese Journal of Interventional Cardiology
2024;32(1):5-8
- CountryChina
- Language:Chinese
-
Abstract:
How to optimize antiplatelet therapy in percutaneous coronary intervention is always a daily problem in clinical practice.In 2023,the research mainly focused on evaluating the efficacy and safety of single-drug therapy strategy of P2Y12 receptor antagonist without aspirin and de-escalation of antiplatelet therapy,which provided more evidence-based evidence for clinical these strategies.The future direction will include applicatian of new therapeutic targets,developing new antiplatelet drugs,using existing drugs to implement more innovative antithrombotic therapy schemes and further research to verify the more widely used contemporary antiplatelet strategies.
- Full text:2024070215501602735经皮冠状动脉介入治疗术后抗血小板治疗2023年度进展.pdf
